Related Experiment Video
Updated: Mar 12, 2026
06:06
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
3.3K
Systematically Optimized Ketoprofen-Loaded Novel Proniosomal Formulation for Periodontitis: In Vitro Characterization
N K Yadav1, Sanju Nanda2, Gajanand Sharma3
1Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India.
AAPS Pharmscitech
|November 16, 2016
Summary
This study introduces proniosomal gels for delivering ketoprofen to treat periodontitis. These novel formulations improved drug delivery and effectively treated experimental periodontal disease, preserving bone and cementum.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Periodontal Therapeutics
Background:
- Ketoprofen is effective for periodontitis, but novel delivery systems are underexplored.
- Experimental periodontal disease (EPD) models are crucial for evaluating new treatments.
Purpose of the Study:
- To explore proniosomal drug delivery of ketoprofen for periodontitis treatment.
- To validate the effectiveness of proniosomal ketoprofen in an EPD model.
Main Methods:
- Proniosomal formulations of ketoprofen were developed using an I-optimal mixture design.
- Characterization included entrapment efficiency, vesicle size, in vitro release, mucoadhesiveness, ex vivo permeation, and retention.
- Optimized gels underwent surface morphology, rheological, texture, and pharmacodynamic evaluations in EPD.
Main Results:
- Ketoprofen proniosomal formulations formed mucoadhesive hydrogels with spherical, flexible vesicles.
- Studies indicated good adhesion, smoothness, and enhanced permeation properties.
- Proniosomal gel treatment improved EPD, preserving bone resorption and cementum compared to a marketed gel.
Conclusions:
- Proniosomes show promise as effective carriers for enhanced ketoprofen delivery in periodontal pockets.
- This approach offers a viable strategy for improving periodontitis treatment outcomes.
Related Concept Videos
01:11Oral Drug Delivery Systems: Delayed-Release Systems
91
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
91
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
130
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
130
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
573
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
573
01:23Oral Drug Delivery Systems: Introduction
147
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
147
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
76
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
76